Vincerx Pharma Inc ( (VINC) ) has released its Q3 earnings. Here is a breakdown of the information Vincerx Pharma Inc presented to its ...

Continued enrollment and dose escalation in Phase 1 study of VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC); additional data expected by early 2025 Completed Phase ...

Continued enrollment and dose escalation in Phase 1 study of VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC); additional data expected by early 2025 Completed ... 12, 2024 ...